S08 E05: ARS' Richard Lowenthal on his mission to transform allergy care

In the latest episode of our podcast, we welcome Richard Lowenthal, CEO, ARS Pharmaceuticals, to explore the company’s mission to address unmet needs in allergy care.

During the conversation, Richard shares insights into his early career at the FDA and the regulatory challenges he faced in bringing ARS’s new nasal spray to treat severe allergic reactions to market. He also discusses the future direction of the company and much more.

A little more on EMJ GOLD’s guest…

Richard Lowenthal is the co-founder, President, and CEO, ARS Pharmaceuticals, with a leadership role since the company’s inception in 2015. Before ARS, he founded Pacific-Link Regulatory Consulting, where he contributed to the development of their diazepam nasal spray. Richard’s extensive background includes senior roles at Cadence Pharmaceuticals, Maxim Pharmaceuticals and Janssen Research Foundation, as well as work as a chemist at the FDA. He holds an M.Sc. in organic chemistry and an MSEL and has chaired the American Association of Pharmaceutical Scientists.